PD-1 and PD-L 1 inhibitors – Competitive Landscape
Dec 02, 2022
PD-1 and PD-L1 Inhibitors: Will They Dominate Over Conventional Cancer Therapies?
The development of tumor therapy in cancer immunotherapy has been aided by programmed death receptor-1 and programmed death protein ligand inhibitors. Since its discovery in 1990, the programmed cell death protein 1 receptor (PD-1) receptor has been known to negatively regulate T-cell mediated immune response via i...
Read More...
Jul 30, 2015
PD-1 and PD-L1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015 – A DelveInsight Report
DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications & Mechanism of Action (MOA).DelveInsight Report, PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015 has received great response and feedback from client...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
